Cipla (LUX:CIPLA) Short-Term Debt: $15 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUX:CIPLA Cipla Ltd LUX:CIPLA
95 GF Score
Price $18.10
GF Value $19.80
! 5 Warning Signs
View Full Analysis

What is Cipla Short-Term Debt?

Cipla LUX:CIPLA 95 Short-Term Debt is $15 Mil as of Mar. 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 95/100 and a GF Value™ of $19.80. The stock has 5 warning signs investors should review.

Cipla's Short-Term Debt for the quarter that ended in Mar. 2026 was $15 Mil.

Cipla's quarterly Short-Term Debt declined from Sep. 2025 ($9 Mil) to Dec. 2025 ($0 Mil) but then increased from Dec. 2025 ($0 Mil) to Mar. 2026 ($15 Mil).

Cipla's annual Short-Term Debt declined from Mar. 2024 ($30 Mil) to Mar. 2025 ($9 Mil) but then increased from Mar. 2025 ($9 Mil) to Mar. 2026 ($15 Mil).

Cipla Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cipla Short-Term Debt Related Terms

Cipla Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cipla's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Short-Term Debt Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.54 63.25 29.75 9.26 15.14

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.26 0.00 8.65 0.00 15.14
LUX:CIPLA
95GF Score
Cipla Ltd LUX:CIPLA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $15 Mil mean?
Cipla (LUX:CIPLA) has a Short-Term Debt of $15 Mil as of Mar. 2026.
Is Cipla's Short-Term Debt too high?
Cipla's current Short-Term Debt is $15 Mil. Overall, Cipla has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Short-Term Debt compare to ZTS and UTHR?
Cipla's Short-Term Debt of $15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cipla's current Short-Term Debt is $15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Short-Term Debt of $15 Mil. The stock's GF Value™ is $19.80, compared to a current price of $18.10 — trading 8.6% below its estimated fair value. The current Short-Term Debt is $15 Mil. Cipla's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Short-Term Debt is $15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.6% below its estimated GF Value™ of $19.80.

Key valuation signals for LUX:CIPLA:

  • Short-Term Debt: $15 Mil
  • GF Value™: $19.80 vs. price of $18.10 (8.6% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
95GF Score

Get the complete analysis for LUX:CIPLA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.80
GF Value